ZORYVE

5 WARNINGS AND PRECAUTIONS Flammability : The propellants in ZORYVE foam, 0.3%, are flammable. Avoid fire, flame, and smoking during and immediately following application. ( 5.1 ) 5.1 Flammability The propellants in ZORYVE foam, 0.3%, are flammable. Avoid fire, flame, and smoking during and immediately following application.

6 ADVERSE REACTIONS The most common adverse reactions (reported in ≥ 1% of patients) are: Seborrheic dermatitis : nasopharyngitis, nausea, and headache. ( 6.1 ) Plaque psoriasis of the scalp and body : headache, diarrhea, nausea, and nasopharyngitis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Arcutis Biotherapeutics, Inc. at 1-844-692-6729 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Seborrheic Dermatitis In two multicenter, randomized, double-blind, vehicle-controlled trials (Trial 203 and STRATUM), 683 adult and pediatric subjects 9 years of age or older with seborrheic dermatitis were treated with ZORYVE foam, 0.3%, or vehicle foam once daily for 8 weeks [see Clinical Studies (14.1) ]. Table 1 presents adverse reactions that occurred in at least 1% of subjects treated with ZORYVE foam, 0.3%. Table 1: Adverse Reactions Reported in ≥1% of Adult and Pediatric Subjects 9 Years of Age and Older with Seborrheic Dermatitis Treated with ZORYVE Foam, 0.3%, for 8 Weeks in Trial 203 and Trial STRATUM Adverse Reaction ZORYVE foam, 0.3% (N=458) n (%) Vehicle foam (N=225) n (%) Nasopharyngitis 7 (1.5) 1 (0.4) Nausea 6 (1.3) 0 (0) Headache 5 (1.1) 0 (0) The following additional adverse reactions were reported in fewer than 1% of subjects treated with ZORYVE foam, 0.3%: diarrhea and insomnia. The adverse reaction profile in pediatric subjects was consistent with that observed in adults [see Use in Specific Populations (8.4) , Clinical Pharmacology (12.3) ] . In 408 subjects who continued treatment with ZORYVE foam, 0.3%, for up to 24 to 52 weeks in an open-label, long-term trial, the adverse reaction profile was consistent with that observed in vehicle-controlled trials. Plaque Psoriasis In two multicenter, randomized, double-blind, vehicle-controlled trials (Trial 204 and ARRECTOR), 734 adult and pediatric subjects 12 years of age and older with plaque psoriasis of the scalp and body were treated with ZORYVE foam, 0.3%, or vehicle foam once daily for 8 weeks [see Clinical Studies (14.2) ]. Table 2 presents adverse reactions that occurred in at least 1% of subjects treated with ZORYVE foam, 0.3%. Table 2: Adverse Reactions Reported in ≥1% of Adult and Pediatric Subjects 12 Years of Age and Older with Plaque Psoriasis of the Scalp and Body Treated with ZORYVE Foam, 0.3%, for 8 Weeks in Trial 204 and Trial ARRECTOR Adverse Reaction ZORYVE foam, 0.3% (N=479) n (%) Vehicle foam (N=255) n (%) Headache 15 (3.1) 3 (1.2) Diarrhea 12 (2.5) 4 (1.6) Nausea 8 (1.7) 0 (0) Nasopharyngitis 6 (1.3) 2 (0.8) The following additional adverse reaction was reported in fewer than 1% of subjects treated with ZORYVE foam, 0.3%: insomnia. The adverse reaction profile in pediatric subjects was consistent with that observed in adults [see Use in Specific Populations (8.4) , Clinical Pharmacology (12.3) ] .

<table width="50%"><caption>Table 1: Adverse Reactions Reported in &#x2265;1% of Adult and Pediatric Subjects 9 Years of Age and Older with Seborrheic Dermatitis Treated with ZORYVE Foam, 0.3%, for 8 Weeks in Trial 203 and Trial STRATUM</caption><col width="35%" align="left" valign="middle"/><col width="35%" align="center" valign="middle"/><col width="30%" align="center" valign="middle"/><thead><tr><th styleCode="Lrule Rrule">Adverse Reaction </th><th styleCode="Rrule">ZORYVE foam, 0.3% (N=458) n (%)</th><th styleCode="Rrule">Vehicle foam (N=225) n (%)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Nasopharyngitis</td><td styleCode="Rrule">7 (1.5)</td><td styleCode="Rrule">1 (0.4)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule"> 6 (1.3)</td><td styleCode="Rrule">0 (0)</td></tr><tr><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">5 (1.1)</td><td styleCode="Rrule">0 (0)</td></tr></tbody></table>

<table width="50%"><caption>Table 2: Adverse Reactions Reported in &#x2265;1% of Adult and Pediatric Subjects 12 Years of Age and Older with Plaque Psoriasis of the Scalp and Body Treated with ZORYVE Foam, 0.3%, for 8 Weeks in Trial 204 and Trial ARRECTOR</caption><col width="35%" align="left" valign="middle"/><col width="35%" align="center" valign="middle"/><col width="30%" align="center" valign="middle"/><thead><tr><th styleCode="Lrule Rrule">Adverse Reaction</th><th styleCode="Rrule">ZORYVE foam, 0.3% (N=479) n (%)</th><th styleCode="Rrule">Vehicle foam (N=255) n (%)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">15 (3.1)</td><td styleCode="Rrule">3 (1.2)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Diarrhea</td><td styleCode="Rrule">12 (2.5)</td><td styleCode="Rrule">4 (1.6)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule">8 (1.7)</td><td styleCode="Rrule">0 (0)</td></tr><tr><td styleCode="Lrule Rrule">Nasopharyngitis</td><td styleCode="Rrule">6 (1.3)</td><td styleCode="Rrule">2 (0.8)</td></tr></tbody></table>